Skip to main content

Rezolute, Inc. (RZLT)

NASDAQ: RZLT · IEX Real-Time Price · USD
5.36
-0.14 (-2.55%)
At close: Nov 26, 2021 1:00 PM
5.34
-0.02 (-0.37%)
After-hours:Nov 26, 2021 1:00 PM EST

Company Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States.

The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.

The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.
Rezolute Logo
CountryUnited States
Founded2010
IndustryBiotechnology
SectorHealth Care
Employees26
CEONevan Elam

Contact Details

Address:
201 Redwood Shores Pkwy Ste 315
Redwood City, California 94065-1134
United States
Phone650 206 4507
Websiterezolutebio.com

Stock Details

Ticker SymbolRZLT
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUS Dollars
CIK Code0001509261

Key Executives

NamePosition
Nevan Charles ElamFounder, Chief Executive Officer and Director
Dr. Brian Kenneth Roberts M.D.Senior Vice President and Head of Clinical Development
Chris MilksVice President of Finance
Michael R. DeperroVice President of Operations
Dr. Davelyn Eaves Hood M.B.A., M.D.Head of Scientific and Patient Affairs
Dr. Sharon Xueyan WangHead of Preclinical Development
Dr. Jeffrey F. Breit Ph.D.Head of Pharmaceutical Sciences

Latest SEC Filings

DateTypeTitle
Nov 12, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 12, 20218-KCurrent report
Nov 10, 2021SC 13G/AStatement of acquisition of beneficial ownership by individuals
Oct 19, 20218-KCurrent report
Oct 14, 2021424B5Prospectus [Rule 424(b)(5)]
Oct 14, 2021424B5Prospectus [Rule 424(b)(5)]
Oct 13, 20218-KCurrent report
Oct 12, 2021424B5Prospectus [Rule 424(b)(5)]
Sep 24, 202110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]
Sep 23, 20218-KCurrent report
View All SEC Filings